Classification criteria for antiphospholipid syndrome (APS) require IgG or IgM isotypes of the anticardiolipin (aCL) antibodies, anti-beta 2 glycoprotein I (anti-beta 2GPI) antibodies, and/or the lupus anticoagulant (LA) to satisfy the laboratory disease definition. Over the past 20 years, non-criteria antiphospholipid antibodies (aPL) directed to other proteins of the coagulation cascade (i.e. prothrombin and/or phosphatidylserine-prothrombin complex) or to some domains of beta 2GPI have been proposed. This task force concentrated and reviewed the literature on data including aPS/PT, antibodies to domain 4/5 of beta 2GPI and the newly described antibodies to protein/HLA-DR complex. In addition, we discussed testing of LA in the 'new' oral anticoagulants' era and the value of triple positivity in the risk assessment of aPL. The conclusions were presented at a special session during the 16(th) International Congress on aPL, Manchester, UK, September 2019.

16th International congress on antiphospholipid antibodies task force report on antiphospholipid syndrome laboratory diagnostics and trends

Radin, Massimo;
2023-01-01

Abstract

Classification criteria for antiphospholipid syndrome (APS) require IgG or IgM isotypes of the anticardiolipin (aCL) antibodies, anti-beta 2 glycoprotein I (anti-beta 2GPI) antibodies, and/or the lupus anticoagulant (LA) to satisfy the laboratory disease definition. Over the past 20 years, non-criteria antiphospholipid antibodies (aPL) directed to other proteins of the coagulation cascade (i.e. prothrombin and/or phosphatidylserine-prothrombin complex) or to some domains of beta 2GPI have been proposed. This task force concentrated and reviewed the literature on data including aPS/PT, antibodies to domain 4/5 of beta 2GPI and the newly described antibodies to protein/HLA-DR complex. In addition, we discussed testing of LA in the 'new' oral anticoagulants' era and the value of triple positivity in the risk assessment of aPL. The conclusions were presented at a special session during the 16(th) International Congress on aPL, Manchester, UK, September 2019.
2023
32
14
1625
1636
Phosphatidylserine-dependent antiprothrombin antibodies; anti-β2Glycoprotein-I antibodies; antibodies to domains of β2-glycoprotein-I
Atsumi, Tatsuya; Chighizola, Cecilia B; Fujieda, Yuichiro; Mackie, Ian; Radin, Massimo; Roubey, Robert; Bertolaccini, Maria Laura
File in questo prodotto:
File Dimensione Formato  
atsumi-et-al-2023-16th-international-congress-on-antiphospholipid-antibodies-task-force-report-on-antiphospholipid.pdf

Accesso aperto

Dimensione 691.04 kB
Formato Adobe PDF
691.04 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1965124
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 3
social impact